Astrazeneca Pharma India Ltd. (ASTRAZEN): Astrazeneca Pharma India 52 Week Low Streak: Second Straight Session of Weakness

Astrazeneca Pharma India 52 Week Low Streak has now extended to its second straight session, with the stock setting another fresh 52-week low at Rs 6,736. Across the streak, the cumulative decline stands at 1.16%, while the latest close was Rs 6,778.95. The supplied data confirms the repeated-low pattern, but it does not establish a company-specific cause for the continued weakness.

On the day, the stock closed below the previous close of Rs 6,785.35 after opening at Rs 6,736 and touching an intraday high of Rs 6,790.5. Turnover was Rs 0.01 crore and market capitalisation stood at Rs 16,963.38 crore. For readers tracking the Astrazeneca Pharma India share price, the key point is not only the one-day fall but the fact that the 52 Week Low Streak is repeating across sessions, which keeps the focus on the pattern rather than a single session move.

Astrazeneca Pharma India 52 Week Low Streak: Consecutive Low Analysis

Metric	Value
Current Price	Rs 6,778.95
Previous Close	Rs 6,785.35
Today's Move	Rs -6.4 (-0.09%)
Open	Rs 6,736
High	Rs 6,790.5
Low	Rs 6,736
Turnover	Rs 0.01 crore
Market Capitalisation	Rs 16,963.38 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,778.95 versus the previous close of Rs 6,785.35, a fall of 0.09%. The stock opened at Rs 6,736, reached a high of Rs 6,790.5, touched a low of Rs 6,736.

The Astrazeneca Pharma India share price today closed at Rs 6,778.95, down Rs 6.4 or 0.09% from the previous close of Rs 6,785.35. The session opened at Rs 6,736, matched the day’s low at Rs 6,736 and rose only to Rs 6,790.5, leaving the close near the lower end of the intraday range. That pattern matters because it shows the stock spent the full session close to its yearly trough rather than recovering meaningfully during trade.

For a stock in a 52 Week Low Streak, the day’s numbers are more informative when read with the streak itself. The current price remains just above the fresh one-year low, while the repeated low print points to a market that is still testing the same downside area session after session. Turnover of Rs 0.01 crore suggests limited value traded on the day, but the supplied data does not support any inference about participation or conviction. Market capitalisation at Rs 16,963.38 crore places the stock in a meaningful listed-company bracket, even as the share price continues to sit near the bottom of its 52-week range.

What the Repeated 52-Week Lows Show

The Astrazeneca Pharma India 52 Week Low Streak now runs for a second straight session, and that repeated pattern is the most important signal in the dataset. The stock first set a fresh 52-week low on 11 September 2026 and then repeated the move on the next relevant session, bringing the cumulative streak decline to 1.16%. In practical terms, the latest trough of Rs 6,736 is the new reference point for the market, replacing the previous one-year low.

That comparison with the earlier low is central to understanding a repeated breakdown. A single-day low can be temporary, but a back-to-back 52 week low pattern shows that the earlier trough did not hold when revisited. The supplied data confirms the continued downside pattern, but it does not provide a company-specific reason for why the stock has remained under pressure. For investors scanning the Astrazeneca Pharma India share price, the question is less about a one-off move and more about whether the repeated lows continue to redraw the near-term base.

Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 16,963.38 crore
P/E Ratio	100.01x
P/B Ratio	18.76x
ROE	23.02%
ROCE	31.24%
EPS	Rs 67.85
Book Value Per Share	Rs 361.68
Dividend Yield	0.53%

Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 100.01x, P/B 18.76x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.

Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 16963.38 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 100.01x, P/B at 18.76x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.53%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.41x, median ROE of 11.61%, median ROCE of 13.18%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	100.01x
Benchmark Median P/E	32.41x
Benchmark Average P/E	48.85x
Benchmark P/E Range	3.34x to 693.7x
Company P/B Ratio	18.76x
Benchmark Median P/B	3.04x
Company ROE	23.02%
Benchmark Median ROE	11.61%
Company ROCE	31.24%
Benchmark Median ROCE	13.18%
Company Market Capitalisation	Rs 16,963.38 crore
Benchmark Median Market Cap	Rs 692.38 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 100.01x, which is above the benchmark median of 32.41x, a difference of +208.58%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.61%, a difference of +98.28%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.18%, a difference of +137.03%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Glenmark Life Sciences Ltd.	ALIVUS	17,005.69	28.2	4.88	18.41	24.61
Suven Pharmaceuticals Ltd.	COHANCE	16,834.28	158.47	4.37	4.02	6.12
Jubilant Pharmova Ltd.	JUBLPHARMA	16,327.91	46.37	2.29	5.97	8.69
Alembic Pharmaceuticals Ltd.	APLLTD	15,963.87	23.02	2.73	12.35	11.74
Concord Biotech Ltd.	CONCORDBIO	15,762	57.24	7.6	13.54	18.04

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 100.01x compared with the displayed peer median of 46.37x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 12.35% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 11.74%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 16,963.38 crore. Among the 5 peers shown, 1 have a larger market capitalisation.

Why Investors Are Watching

• The Astrazeneca Pharma India 52 Week Low Streak has reached a second straight session, keeping the stock at a fresh one-year trough.
• The cumulative decline across the streak is 1.16%, which helps frame the repeated breakdown beyond a single day’s move.
• The latest low of Rs 6,736 is the key level now being tested by the market after the prior one-year floor was broken.
• The stock still trades at a premium valuation versus the supplied pharma peer medians, even with the weaker price pattern.
• Investors following Astrazeneca Pharma India Stock Performance will likely monitor whether the repeated low is followed by stabilisation or another lower print.

About the Company

Astrazeneca Pharma India Ltd. is listed on the NSE and BSE and operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. The company’s reported market capitalisation is Rs 16,963.38 crore. Its financial snapshot in the supplied data shows EPS of Rs 67.85, book value of Rs 361.68, ROE of 23.02%, ROCE of 31.24% and dividend yield of 0.53%.

For readers using this Astrazeneca Pharma India Share Price Today update, the company profile is important because it separates business metrics from the current price pattern. The stock’s 52 Week Low Streak is a market event, while the operating and valuation data provide the wider context. The share price can remain weak even when return ratios are relatively strong, which is why both the stock price and the underlying fundamentals matter in the same discussion.

Track Astrazeneca Pharma India on Univest

Follow the Astrazeneca Pharma India 52 Week Low Streak page on Univest for updated share price context, sector comparison and stock news coverage. The aim is to keep one place for the latest Astrazeneca Pharma India Stock Analysis, recent market performance and valuation snapshot as the price continues to trade near a fresh yearly low.

For investors monitoring Stocks At One Year Low Today, the useful question is whether the repeated low begins to stabilise or if the streak extends further. Univest will continue to track the Astrazeneca Pharma India Share Price alongside the company’s fundamentals, sector backdrop and peer valuation context.

Frequently Asked Questions

Why is Astrazeneca Pharma India still hitting 52-week lows?

Ans. The supplied data confirms a repeated 52-week low pattern for Astrazeneca Pharma India, but it does not establish a company-specific cause. The key facts are the second straight session of weakness, the fresh low of Rs 6,736 and the 1.16%.

How many sessions has Astrazeneca Pharma India been at a fresh 52-week low?

Ans. The stock has now set a fresh 52-week low for a second straight session. That means the breakdown is not limited to one day and has repeated across consecutive trading sessions.

What is the current Astrazeneca Pharma India share price?

Ans. The latest close in the supplied data is Rs 6,778.95. That was below the previous close of Rs 6,785.35 and came after the stock printed a fresh 52-week low at Rs 6,736 during the session.

How far has Astrazeneca Pharma India fallen across the streak?

Ans. Across the current streak, Astrazeneca Pharma India has moved lower by 1.16%. That cumulative figure is useful because it captures the repeated nature of the 52 Week Low Streak rather than just the one-day change.

Is Astrazeneca Pharma India expensive compared with peers?

Ans. Based on the supplied peer and sector data, Astrazeneca Pharma India trades at a higher valuation than the median pharmaceutical peer on both P/E and P/B. Its returns on equity and capital employed are also above the industry medians.

What should investors track next in Astrazeneca Pharma India?

Ans. Investors should watch whether Rs 6,736 holds as the immediate reference low, whether the stock prints another lower trough, and whether the broader valuation and company fundamentals remain consistent with the current price pattern.

Does the repeated 52-week low mean the stock has made an all-time low?

Ans. No. The supplied data confirms a fresh 52-week low, not an all-time low. A record-low statement should only be used when an all-time-low value is explicitly supplied and supported by the numbers.

Where can readers follow Astrazeneca Pharma India Stock News and analysis?

Ans. Readers can follow the Astrazeneca Pharma India Share Price, company news, sector context and peer comparison on Univest. The page is useful for tracking the next move after a repeated one-year low pattern.

Track Astrazeneca Pharma India Ltd. (ASTRAZEN) Share Price on Univest

Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.